ArticleFrontiers in cardiovascular medicine2026
Systemic inflammation is associated with increased risk of death in population with atherosclerotic cardiovascular disease and chronic kidney disease-a Danish national register study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Systemic inflammation (SI), indicated by elevated C-reactive protein (CRP) levels, is known to increase the risk of major adverse cardiovascular events (MACE) and mortality. This study aims to investigate the association between SI and mortality in the Danish population diagnosed with atherosclerotic cardiovascular disease ASCVD and chronic kidney disease CKD. Methods: We identified 19,159 individuals with incident ASCVD and CKD between 2012 and 2022 in Danish national health registers. SI was defined by at least two CRP measurements between 2 mg/L and 20 mg/L within a six-month period. Cox proportional hazards models were employed to assess the relationship between SI and mortality, adjusting for relevant confounders. Results: Among the cohort, 68% were observed with SI. SI were associated with significantly higher risk of mortality, with a hazard ratio (HR) of 2.06 (95% CI: 1.92-2.21) for death and 1.66 (95% CI: 1.57-1.77) for 'MACE or death'. The results were consistent in all subgroup analyses and sensitivity analyses, including in men and women separately, and using different definitions of SI. Conclusion: This study demonstrates that SI is prevalent among patients with ASCVD and CKD being strongly associated with higher risk of mortality and MACE. These findings suggest that SI could serve as a valuable marker to identify patients with ASCVD and CKD who are at particularly high risk and may benefit from targeted preventive interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.